TurnKey Capital, Inc. (TKCI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
TurnKey Capital, Inc. (TKCI) trades at $0.0449. TurnKey Capital, Inc. , operating as HealthSpan Medical Systems, focuses on developing marijuana-based intravenous therapy infusion blends for healthcare practitioners. Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for TKCI: TKCI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TKCI against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TKCI: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →TurnKey Capital, Inc. (TKCI) Financial Services Profile
TurnKey Capital, Inc., through its HealthSpan Medical Systems subsidiary, develops marijuana-based intravenous therapy infusion blends, targeting healthcare practitioners within the evolving medical cannabis sector, while operating with a high profit margin and trading on the OTC market.
What Is the Investment Thesis for TKCI?
TurnKey Capital, Inc. (TKCI), through its HealthSpan Medical Systems subsidiary, presents a high-risk, high-reward investment profile. The company's focus on marijuana-based intravenous therapy infusion blends positions it within a niche segment of the rapidly growing medical cannabis market. The company's high profit margin of 98.2% suggests strong pricing power or cost efficiency, but this should be viewed cautiously given the company's size and OTC listing. Growth catalysts include potential regulatory approvals for its IV infusion blends and expansion into new markets. However, the company faces significant risks, including regulatory uncertainty, competition from established pharmaceutical companies, and the inherent volatility of the OTC market. Investors should carefully consider these factors before investing in TKCI.
Based on FMP financials and quantitative analysis
TKCI Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
- P/E ratio of 27.42 suggests investors are paying a premium for each dollar of earnings, reflecting potential growth expectations.
- Profit margin of 98.2% is exceptionally high, potentially unsustainable, and warrants further investigation.
- The company operates in the evolving medical cannabis sector, offering both opportunities and regulatory challenges.
- Listing on the OTC market signifies higher risk and lower liquidity compared to major exchanges.
Who Are TKCI's Competitors?
TKCI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CHYL Unified Global Corp. | $0.46 | +0.00% | $27.1M | 43 |
| NIHL New Infinity Holdings, Ltd. | $0.10 | +0.00% | $10.8M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| INACU Indigo Acquisition Corp. | $12.08 | +16.94% | $34.9M | 60 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TKCI's Key Strengths?
Focus on a niche market (medical cannabis IV infusions).
- High profit margin (98.2%).
- Innovative product offerings.
- Early mover advantage in a growing market.
What Are TKCI's Weaknesses?
Small market capitalization ($0.00B).
- OTC listing indicates higher risk and lower liquidity.
- Limited operating history.
- Dependence on regulatory approvals.
What Could Drive TKCI Stock Higher?
Potential regulatory approvals for HealthSpan's IV infusion blends could drive significant growth.
- Increasing acceptance and legalization of medical cannabis may expand the market for HealthSpan's products.
- Partnerships with healthcare providers could lead to increased adoption of HealthSpan's therapies.
- Expansion into new geographic markets as regulations evolve.
What Are the Key Risks for TKCI?
Financial-distress signal — its Altman Z-Score of 0.05 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory uncertainty in the cannabis industry could hinder HealthSpan's growth.
- Competition from larger, more established companies could erode market share.
- Changes in consumer preferences could impact demand for HealthSpan's products.
- The company's small market capitalization and OTC listing increase investment risk.
- Limited financial disclosure makes it difficult to assess the company's financial health.
What Are the Growth Opportunities for TKCI?
- Expansion into new geographic markets: As regulations surrounding medical cannabis evolve, HealthSpan Medical Systems has the opportunity to expand its market reach beyond Florida. Targeting states with favorable cannabis laws and a growing demand for alternative therapies could significantly increase revenue. The medical cannabis market is projected to reach $55 billion by 2026, providing a substantial addressable market for HealthSpan's products.
- Development of new IV infusion blends: HealthSpan Medical Systems can invest in research and development to create new IV infusion blends targeting specific medical conditions. By expanding its product portfolio, the company can attract a wider range of healthcare practitioners and patients. The market for targeted drug delivery systems is expected to grow at a CAGR of 8% through 2028, driven by the increasing demand for personalized medicine.
- Partnerships with healthcare providers: Collaborating with hospitals, clinics, and other healthcare providers can provide HealthSpan Medical Systems with access to a broader patient base and enhance its credibility within the medical community. Strategic partnerships can also facilitate the integration of HealthSpan's IV infusion blends into existing treatment protocols. The healthcare provider market is highly fragmented, offering numerous opportunities for collaboration.
- Securing regulatory approvals: Obtaining regulatory approvals from relevant authorities, such as the FDA, can significantly enhance the marketability and acceptance of HealthSpan's IV infusion blends. Regulatory approvals can also provide a competitive advantage by creating barriers to entry for other companies. The regulatory landscape for medical cannabis is constantly evolving, requiring companies to stay informed and adapt to changing requirements.
- Direct-to-consumer marketing: HealthSpan Medical Systems can explore direct-to-consumer marketing strategies to raise awareness of its IV infusion blends and drive demand. This could involve online advertising, social media campaigns, and educational materials targeted at patients and healthcare consumers. The direct-to-consumer pharmaceutical market is growing rapidly, driven by the increasing use of online channels and the demand for convenient access to healthcare information.
What Are TKCI's Competitive Advantages?
- Specialized IV infusion blends offer a unique delivery method.
- Focus on the medical cannabis market provides a niche.
- Proprietary formulations may create a competitive advantage.
- Early mover advantage in the emerging medical cannabis IV therapy market.
What Does TKCI Do?
HealthSpan Medical Systems, Inc., operating under TurnKey Capital, Inc. (TKCI), specializes in the development of marijuana-based intravenous (IV) infusion blends tailored for healthcare practitioners. Founded in 2018 and headquartered in Ft. Lauderdale, Florida, the company aims to provide innovative solutions within the medical cannabis industry. HealthSpan's core business revolves around creating specialized IV infusion blends that leverage the therapeutic properties of marijuana. These blends are designed to be administered by healthcare professionals, potentially offering targeted and efficient delivery of cannabinoids for various medical applications. The company operates within the broader financial services sector, specifically categorized as a shell company, while focusing its operational activities on the development and marketing of its unique IV infusion products. As a relatively young company, HealthSpan Medical Systems is navigating the evolving regulatory landscape of the cannabis industry, seeking to establish itself as a key player in the development of novel medical cannabis therapies. The company's success hinges on its ability to innovate, secure regulatory approvals, and effectively market its products to healthcare providers.
What Products and Services Does TKCI Offer?
- Develop marijuana-based intravenous (IV) infusion blends.
- Target healthcare practitioners with specialized medical cannabis therapies.
- Formulate IV infusions for potential medical applications.
- Operate within the medical cannabis industry.
- Seek regulatory approvals for their products.
- Market and distribute IV infusion blends to healthcare providers.
How Does TKCI Make Money?
- Develop and manufacture marijuana-based IV infusion blends.
- Market and sell products to healthcare practitioners.
- Generate revenue through product sales.
- Focus on specialized medical cannabis therapies.
What Industry Does TKCI Operate In?
TurnKey Capital, Inc. operates within the financial services sector, specifically as a shell company with its primary business being HealthSpan Medical Systems in the medical cannabis industry. The medical cannabis market is experiencing rapid growth, driven by increasing legalization and acceptance of cannabis-based therapies. However, the industry is also characterized by intense competition, regulatory uncertainty, and evolving consumer preferences. Companies like TKCI face the challenge of navigating this complex landscape while competing with larger, more established players. Competitors include companies focused on cannabis-based pharmaceuticals and alternative delivery methods.
Who Are TKCI's Key Customers?
- Healthcare practitioners (doctors, nurses, etc.)
- Hospitals and clinics
- Patients seeking alternative medical cannabis therapies
Insider Activity
The most recent 9 insider filings for TurnKey Capital, Inc. break down as 5 sales and 4 purchases. On net that is roughly 2K shares disposed (about $80K), a signal worth weighing alongside the fundamentals.
Key Financial Metrics
Return on equity for TurnKey Capital, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 23.58 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
TurnKey Capital, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.05 places it in the distress zone, a signal of elevated financial risk.
Company Profile
TurnKey Capital, Inc. operates in the Software - Application industry within the Technology sector. It is headquartered in Murrieta, US. The company is led by CEO Dawnte Bailey. TKCI has traded publicly since 2014.
TKCI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on a niche market (medical cannabis IV infusions).
- High profit margin (98.2%).
- Innovative product offerings.
- Early mover advantage in a growing market.
Bear Case
- Small market capitalization ($0.00B).
- OTC listing indicates higher risk and lower liquidity.
- Limited operating history.
- Dependence on regulatory approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
TKCI Latest News
No recent news available for TKCI.
TKCI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TKCI.
Price Targets
Wall Street price target analysis for TKCI.
TKCI MoonshotScore
What does this score mean?
The MoonshotScore rates TKCI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Neil Swartz
CEO
Neil Swartz serves as the CEO of TurnKey Capital, Inc. While specific details on his prior experience and educational background are not available, he leads the company's strategic direction and operational execution. His role involves overseeing the development and marketing of HealthSpan Medical Systems' marijuana-based IV infusion blends. He is responsible for navigating the regulatory landscape and fostering relationships with healthcare providers.
Track Record: As CEO, Neil Swartz has overseen the development of HealthSpan Medical Systems' product line and its entry into the medical cannabis market. Specific milestones and achievements under his leadership are not detailed in the provided information. His focus is on establishing the company as a provider of innovative medical cannabis therapies.
TKCI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that TurnKey Capital, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial information available to the public, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. This tier is distinct from NYSE or NASDAQ listings, which have stringent listing requirements and continuous reporting obligations.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing.
- Low liquidity can make it difficult to exit positions.
- Potential for price manipulation due to lack of regulatory oversight.
- Higher risk of fraud or misrepresentation compared to listed companies.
- OTC Other stocks are generally more volatile than those on major exchanges.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Research the backgrounds of the company's management team.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal disputes involving the company.
- Company incorporation in 2018 suggests some operating history.
- Focus on developing medical cannabis therapies indicates a specific business purpose.
- Headquarters in Ft. Lauderdale, Florida provides a physical location.
- CEO Neil Swartz is identified, providing a point of contact.
- Development of marijuana-based IV infusion blends demonstrates product development efforts.
What Investors Ask About TurnKey Capital, Inc. (TKCI) — Financial Services
What does TurnKey Capital, Inc. do?
TurnKey Capital, Inc., through its HealthSpan Medical Systems subsidiary, focuses on developing marijuana-based intravenous (IV) infusion blends for healthcare practitioners. These specialized blends are designed to deliver cannabinoids directly to patients, potentially offering targeted and efficient therapeutic benefits. The company operates within the evolving medical cannabis industry, aiming to provide innovative solutions to healthcare providers seeking alternative treatment options.
What do analysts say about TKCI stock?
There is currently no available analyst coverage for TurnKey Capital, Inc. (TKCI). The company's small market capitalization and OTC listing likely contribute to the lack of analyst attention. Investors should conduct their own thorough research and due diligence before investing in TKCI, considering the inherent risks associated with micro-cap and OTC stocks.
What are the main risks for TKCI?
TurnKey Capital, Inc. (TKCI) faces several significant risks. Regulatory uncertainty in the cannabis industry poses a major threat, as changes in laws and regulations could impact the company's ability to operate and market its products. Competition from larger, more established pharmaceutical companies and other cannabis-based therapy providers could erode market share.
What are the key factors to evaluate for TKCI?
Evaluate TKCI on fundamentals, analyst consensus, and risk factors. TurnKey Capital, Inc. (TKCI), through its HealthSpan Medical Systems subsidiary, presents a high-risk, high-reward investment profile. Not financial advice.
How frequently does TKCI data refresh on this page?
TKCI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TKCI's recent stock price performance?
TurnKey Capital, Inc. (TKCI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a niche market (medical cannabis IV infusions). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TKCI overvalued or undervalued right now?
TurnKey Capital, Inc. (TKCI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TKCI before investing?
Before investing in TurnKey Capital, Inc. (TKCI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- OTC stocks are inherently riskier than exchange-listed stocks.
- Financial data may not be fully reliable due to limited disclosure.